VINEETLAB vs WOCKPHARMA: Stock Comparison

Vineet Laboratories Limited vs Wockhardt Ltd

Live data: 29 April 2026, 4:01 PM IST • Source: NSE and company filings

Wockhardt Ltd is the larger company by market capitalisation. Wockhardt Ltd shows faster revenue growth, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Vineet Laboratories Limited and Wockhardt Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, VINEETLAB is more favourable on 0 of 10 scored metrics and WOCKPHARMA on 8These counts are context-free and are not an overall rating.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,362 Cr vs ₹73 Cr
EPS
WOCKPHARMA has higher earnings per share
₹13.1 vs ₹-20.47
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs 11.05%
Qtr Sales Growth
WOCKPHARMA has stronger quarterly sales growth
29.9% vs -68.8%
Qtr Profit Growth
WOCKPHARMA has stronger quarterly profit growth
688% vs 59.2%
ROCE
WOCKPHARMA has a higher ROCE
7.55% vs -28%
Net Margin
WOCKPHARMA has a higher net margin
3.3% vs -26.92%
Operating Margin
WOCKPHARMA has a higher operating margin
19.3% vs -22.4%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricVINEETLABWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricVINEETLABWOCKPHARMA
Live Price₹38.55₹1,866.9
Day Change5.79%-1.55%
Volume2.02 L7.17 L
52-Week High₹49.99₹2,422.3
52-Week Low₹27.96₹1,086.7
Distance from 52W High-22.88%-22.93%

Valuation

MetricVINEETLABWOCKPHARMA
Market Cap₹73 Cr₹30,362 Cr
P/E Ratio144.46x
P/B Ratio6.23x
EPS₹-20.47₹13.1
Book Value₹15.84₹304
Dividend Yield0%0%

Growth

MetricVINEETLABWOCKPHARMA
Revenue Growth (TTM YoY)11.05%26%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth-68.8%29.9%
Qtr Profit Growth59.2%688%

Profitability & Leverage

MetricVINEETLABWOCKPHARMA
ROE6.11%
ROCE-28%7.55%
Net Margin-26.92%3.3%
Operating Margin-22.4%19.3%
Debt to Equity2.73x0.45x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricVINEETLABWOCKPHARMA
Promoter Holding5.98% 6.48 pp49.08%
FII Holding0.36% 0.36 pp7.09% 0.1 pp
DII Holding10.96% 0.41 pp
Public Holding93.66% 6.12 pp32.83% 0.52 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Vineet Laboratories Limited and Wockhardt Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.